Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults…
Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Ozempic® improved maximum walking distance by 13% vs placebo in adults with…
The DDC Group is Transforming, Unifying All DDC Companies under a Single, Global BPM Brand
The DDC Group unifies all "DDC" operations and brands to drive exceptional…
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor…
BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology
Advancing Precision Oncology with AI-Driven Multiomics for Optimized Therapy Selection and Improved…
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a…
SYNERGIA MEDICAL ANNOUNCES STRONG RESULTS FOR NAO.VNS FIRST-IN-HUMAN STUDY
Primary safety endpoint met - No serious adverse events reported over 3-monthsRobust…
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
February 14, 2025 16:05 ET | Source: Dyne Therapeutics, Inc. - Data…
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimers Disease
February 13, 2025 08:00 ET | Source: NKGen Biotech The results from…
Rockwell Automation Releases 2024 Sustainability Report
NEW DELHI, Feb. 7, 2025 /PRNewswire/ -- Rockwell Automation, Inc. (NYSE: ROK), the…